Trials / Completed
CompletedNCT00092027
A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Compare the Safety and Tolerability of an Oral Buffered Solution of Alendronate Sodium 70 mg Once-Weekly Versus Placebo for the Treatment of Osteoporosis in Postmenopausal Women
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 454 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- Female
- Age
- 25 Years
- Healthy volunteers
- Not accepted
Summary
This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0217, alendronate sodium/Duration of Treatment: 6 months | |
| DRUG | Comparator: placebo / Duration of Treatment: 6 months |
Timeline
- Start date
- 2003-03-19
- Primary completion
- 2004-03-15
- Completion
- 2004-03-15
- First posted
- 2004-09-24
- Last updated
- 2024-08-14
Source: ClinicalTrials.gov record NCT00092027. Inclusion in this directory is not an endorsement.